Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2022

01.06.2022 | editorial

COVID-19: New disease mechanism is simultaneously a therapeutic target

verfasst von: Prof. Dr. Clemens A. Schmitt

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Excerpt

A characteristic feature of severe cases of COVID-19 (coronavirus disease 2019) is the derailment of pro-inflammatory messenger substances with overactivation of immune cell networks, which then no longer help with warding off viruses, but harm organs, above all the lungs. What exactly causes this inflammatory response to snowball is not however sufficiently understood. A hypothesis in this regard has been put forward by a research team headed up by Univ.-Prof. Clemens A. Schmitt, Member of the Board of Directors of the Department of Haematology and Oncology at Kepler University Hospital, who is also professor in this discipline at Johannes Kepler University Linz (JKU). This hypothesis has been investigated in Linz under the overall control of Prof. Schmitt’s team with participation of the Berliner Charité and many other international cooperation partners. The results were recently published in the prestigious international journal Nature [1]. …
Literatur
1.
Zurück zum Zitat Lee S, Yu Y, Trimpert J, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. 2021;599(7884):283–9.CrossRef Lee S, Yu Y, Trimpert J, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. 2021;599(7884):283–9.CrossRef
Metadaten
Titel
COVID-19: New disease mechanism is simultaneously a therapeutic target
verfasst von
Prof. Dr. Clemens A. Schmitt
Publikationsdatum
01.06.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00813-w

Weitere Artikel der Ausgabe 2/2022

memo - Magazine of European Medical Oncology 2/2022 Zur Ausgabe